Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
"Racemetyrosine" - Google News
Get the latest updates from "Racemetyrosine" - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated over 3 years ago
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 - StreetInsider.com
over 3 years ago
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer...
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 - StreetInsider.com
over 3 years ago
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer...
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 - Yahoo Finance
over 3 years ago
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer...
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 - GlobeNewswire
over 3 years ago
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer...
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 - GlobeNewswire
over 3 years ago
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer...
Form 10-Q TYME TECHNOLOGIES, INC. For: Dec 31 - StreetInsider.com
over 3 years ago
Form 10-Q TYME TECHNOLOGIES, INC. For: Dec 31 StreetInsider.com
Tyme Technologies Shares Hit 52-Week Low After Discontinuing Trial - MarketWatch
over 3 years ago
Tyme Technologies Shares Hit 52-Week Low After Discontinuing Trial MarketWatch
Tyme Technologies Discontinues Trial for Pancreatic Cancer Treatment - MarketWatch
over 3 years ago
Tyme Technologies Discontinues Trial for Pancreatic Cancer Treatment MarketWatch
Tyme Technologies (TYME) Announces Discontinuation of SM-88 and MPS Tria - StreetInsider.com
over 3 years ago
Tyme Technologies (TYME) Announces Discontinuation of SM-88 and MPS Tria StreetInsider.com
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer - Yahoo Finance
over 3 years ago
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic...
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer - BioSpace
over 3 years ago
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic...
TYME falls 35% as study culled after SM-88 fails to improve survival in pancreatic cancer - Seeking Alpha
over 3 years ago
TYME falls 35% as study culled after SM-88 fails to improve survival...